Stuart Chaffee, currently Chief Executive Officer of QuantX Biosciences, brings over two decades of experience in the biotechnology and biopharma industry. He has played a pivotal role in the inception of four publicly traded biotechnology companies and has successfully raised over $900 million in private and public capital. In his previous operating role as Chief Business Officer at Affinivax, Inc., Dr. Chaffee was instrumental in driving the company’s strategic growth, culminating in its acquisition by GSK for up to $3.3 billion. His expertise in business development and advising innovative biotech ventures positions him to provide invaluable strategic guidance as SpyBiotech advances its clinical pipeline and expands its proprietary SpyTag/SpyCatcher™ and other related protein superglue technology.

Dr. Chaffee received a BS in chemistry from The College of William and Mary, a Ph.D. in organic chemistry from Yale University, and an MBA in finance from the Wharton School of the University of Pennsylvania.